Evommune (EVMN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.89
- Estimate
- -$0.67
- Surprise
- -32.8%
- Score today
- 4.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Evommune (EVMN) reported a wider loss than forecast — diluted EPS of -$0.89 against the -$0.67 estimate (a 32.8% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates EVMN Sell at 4.5/10; no pre/post engine snapshot brackets this report.
1 of the last 3 quarters beat the estimate; this quarter's -32.8% surprise compares with a -24.6% four-quarter average. Next scheduled report: 2026-11-16.
What argues against it
- Quality below floor (3.4 < 4.0)
- Momentum score 1.5/10 — below 4.5 minimum
- Death cross — 50-day MA below 200-day MA
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.27
- Price target
- $24.03
- Stop
- $11.41
- Upside to target
- +95.8%
- Reward-to-risk
- 7.7:1
Model outputs from TrendMatrix’s engine as of 2026-09-05 — shown for context, not personalized investment advice.
EVMN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $445.3M
- P/E (fwd)
- -3.6
- 52-week range
- $10.47–$33.20
- Off 52-week high
- 63.0%
- RSI (14)
- 33
- Volume vs avg
- 0.65×
- Score today
- 4.5/10